Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Debt / NOTE 1.250% 5/1
-
Number of holders
-
47
-
Total 13F principal, excl. options
-
362M
-
Principal change
-
+29.9M
-
Total reported value, excl. options
-
$366M
-
Value change
-
+$30.2M
-
Number of buys
-
19
-
Number of sells
-
-14
-
Price
-
$1.01
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2023
50 filings reported holding 09061GAK7 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2023.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 has 47 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $362M of principal
.
Largest 10 bondholders include Voya Investment Management LLC ($83.6M of principal), MACKAY SHIELDS LLC ($76.3M of principal), LAZARD ASSET MANAGEMENT LLC ($50.9M of principal), Wellesley Asset Management ($42.5M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($35.7M of principal), Lombard Odier Asset Management (Europe) Ltd ($16.4M of principal), DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main ($14.5M of principal), Thrivent Financial for Lutherans ($13M of principal), VICTORY CAPITAL MANAGEMENT INC ($12.8M of principal), and STATE STREET CORP ($12.8M of principal).
This table shows the top 47 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.